scispace - formally typeset
S

Sandra Gordon

Researcher at Lund University

Publications -  13
Citations -  251

Sandra Gordon is an academic researcher from Lund University. The author has contributed to research in topics: ATPase & Mode of action. The author has an hindex of 6, co-authored 12 publications receiving 204 citations. Previous affiliations of Sandra Gordon include University of Saskatchewan.

Papers
More filters
Journal ArticleDOI

Selective killing of candidate AML stem cells by antibody targeting of IL1RAP.

TL;DR: It is demonstrated that IL1RAP is a promising new therapeutic target in AML by achieving selective killing of AML MNC, CD34+CD38+, and CD34-CD38- cells using a monoclonal antibody.
Journal ArticleDOI

Distinct stress-inducible and developmentally regulated heat shock transcription factors in xenopus oocytes

TL;DR: The detection of distinct stress-inducible and developmentally regulated HSE-binding activities of endogenous oocyte factors and the kinetics of HSF1 activation in oocytes suggests that a key protein(s) regulating attenuation of the stress response is present at exceedingly low levels or is somehow modified during preembryonic development.
Journal ArticleDOI

Identification of Antifungal H+-ATPase Inhibitors with Effect on Plasma Membrane Potential.

TL;DR: The present inhibitors could serve as a starting point for the development of new antifungal agents with a novel mode of action, and reveal a dual mechanism for the previously identified cationic peptide BM2, revealing fungal membrane disruption, in addition to Pma1 inhibition.
Journal ArticleDOI

Tetrahydrocarbazoles are a novel class of potent P-type ATPase inhibitors with antifungal activity.

TL;DR: It is found that tetrahydrocarbazoles inhibit adenosine triphosphate (ATP) hydrolysis of thefungal H+-ATPase, depolarize the fungal plasma membrane and exhibit broad-spectrum antifungal activity.
Journal ArticleDOI

Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo

TL;DR: Valproate treatment at pharmacologically relevant doses resulted in upregulation of CD20 in vivo, and also in expected epigenetic modifications, which suggests that pre-treatment with valproate or other HDACis before anti-CD20 therapy could be advantageous in CD20-low B-cell lymphomas.